CALCIUM GLUCONATE INJECTION, USP 10% SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CALCIUM GLUCONATE

제공처:

BAXTER CORPORATION

ATC 코드:

B05XA19

INN (국제 이름):

CALCIUM GLUCONATE

복용량:

100MG

약제 형태:

SOLUTION

구성:

CALCIUM GLUCONATE 100MG

관리 경로:

INTRAVENOUS

패키지 단위:

15G/50G

처방전 유형:

Ethical

제품 요약:

Active ingredient group (AIG) number: 0108566002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2021-12-08

제품 특성 요약

Calcium Gluconate Injection, USP 10% - Prescribing Information
Page 1 of 9
PRESCRIBING INFORMATION
CALCIUM GLUCONATE INJECTION, USP 10%
Solution, 100 mg / mL (0.446 mEq / mL)
For Intravenous Use
Pharmacy bulk package: 50 000 mg per 500 mL
ATC Code: B05BB01
Electrolyte Replenisher
BAXTER CORPORATION
7125 Mississauga Road
Mississauga, ON L5N 0C2
Date of Preparation:
December 8, 2021
Submission
Control No: 242725
Baxter and Clearflex are trademarks of Baxter International Inc.
Calcium Gluconate Injection, USP 10% - Prescribing Information
Page 2 of 9
TABLE OF CONTENTS
1.
INDICATIONS
.............................................................................................................
3
2.
CONTRAINDICATIONS
.............................................................................................
3
3.
DOSAGE AND
ADMINISTRATION...........................................................................
3
3.1
Recommended Dose and Dosage
Adjustment..........................................................3
3.2
Administration
.......................................................................................................4
3.3
Reconstitution
........................................................................................................5
4.
OVERDOSAGE
............................................................................................................
5
5.
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................. 5
6.
WARNINGS AND PRECAUTIONS
............................................................................
6
6.1
Special Populations
................................................................................................7
6.1.1
Pregnant
Women....................................................................................................7
6.1.2
Breast-feeding........................................................................................................7
7.
ADVERSE REACTIONS
..............................................................................